CytomX Therapeutics, Inc. announced that it has entered into a clinical trial collaboration and supply agreement with Merck for CytomX's first-in-human Phase 1 clinical trial assessing the clinical activity of CX-801, a dually-masked interferon-alpha2b cytokine in combination with Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.75 USD | -2.23% | -6.42% | +12.90% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
125.9 USD | -0.15% | -3.72% | 319B | ||
1.75 USD | -2.23% | -6.42% | 139M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.90% | 139M | |
+8.38% | 115B | |
+10.13% | 105B | |
-11.69% | 22.71B | |
+2.21% | 21.83B | |
-10.88% | 18.18B | |
-41.90% | 16.52B | |
-16.00% | 16.01B | |
+2.28% | 14.14B | |
+20.54% | 10.71B |
- Stock Market
- Equities
- CTMX Stock
- News CytomX Therapeutics, Inc.
- CytomX Therapeutics, Inc. Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with Keytruda® (pembrolizumab)